Presence of human immunodeficiency virus (HIV) type 1 and HIV-1-specific antibodies in cervicovaginal secretions of infected mothers and in the gastric aspirates of their infants

Journal of Infectious Diseases

Volumn 173, Issue 4, 1996, Pages 1001-1004

  Nielsen, Karin ^b   Boyer, Pamela ^b   Dillon, Maryanne ^b   Wafer, Deborah ^b   Wei, Lian S ^b   Garratty, Eileen ^b   Dickover, Ruth E ^b   Bryson, Yvonne J ^a  

^a UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PERINATAL INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RNA ANALYSIS; STOMACH SECRETION; STOMACH SUCTION; VAGINA SECRETION; VIRUS SHEDDING; VIRUS TRANSMISSION;

EID: 0030006519     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.4.1001     Document Type: Article

References (15)

1. Chin J. Current and future dimensions of the HIV/AIDS pandemic in women and children. Lancet 1990;336:221-4.
2. Stiehm ER, Vink P. Transmission of human immunodeficiency virus by breastfeeding. J Pediatr 1991;118:410-2.
3. Krivine A, Firtion G, Cao L, Francoual C, Henrion R, Lebon P. HIV replication during the first weeks of life. Lancet 1992;339:1187-9.
4. Pomerantz RJ, Monte SM, Donegan SP, et al. Human immunodeficiency virus infection of the uterine cervix. Ann Intern Med 1988;108:321-7.
5. Dickover R, Herman S, Garratty E, Von Seidlein L, Boyer P, Bryson YJ. Maternal HIV RNA levels are directly related to perinatal transmission risk and significantly reduced by ZDV treatment. J Cell Biochem 1995;21B(suppl):233.
6. Weiser B, Nachman S, Tropper P, et al. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci USA 1994;91:8037-41.
7. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
8. Bryson YJ, Luzuriaga K, Sullivan J, Wara D. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992;321:1246-7.
9. Dickover RE, Dillon M, Gillette SG, et al. Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected children. J Infect Dis 1994;170:1279-84.
10. Martin N, Levy J, Legg H, Weintrub P, Cowan M, Wara D. Detection of infection with human immunodeficiency virus (HIV) type 1 in infants by an anti-HIV immunoglobulin A assay using recombinant proteins. J Pediatr 1991;118:354-8.
11. O'Sullivan MJ, Boyer PJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine collaborative working group. Am J Obstet Gynecol 1993;168:1510-6.
12. European Collaborative Study. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 1991;337:253-60.
13. Baba TW, Koch J, Mittler ES, et al. Mucosal infection of neonatal rhesus monkeys with cell-free SIV. AIDS Res Hum Retroviruses 1994;10:351-7.
14. Burnett P, VanCott T, Polonis V, Redfield R, Birx D. Serum IgA-mediated neutralization of HIV type 1. J Immunol 1994;152:4642-8.
15. Yolken R, Miotti P, Dallabetta G, Chiphangwi J, Clayman B, Viscidi R. Secretory immune response to HIV and perinatal transmission [abstract]. Pediatr Res 1993;33:189A.